/DMAC
DMAC Stock - DiaMedica Therapeutics Inc.
Healthcare|BiotechnologyNASDAQ
$8.48+2.05%
+$0.17 (+2.05%) • Dec 19
65
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).46
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.68
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+-1.8%upside
Target: $8.33
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for DMAC
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$8.40 – $8.56
TARGET (TP)$8.33
STOP LOSS$7.80
RISK/REWARD1:-0.2
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.30
52W High$10.42
52W Low$3.19
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-26,681,000 | $-21,267,000 | $-14,001,000 | $-13,646,000 | $-12,699,000 |
| Net Income | $-24,444,000 | $-19,381,000 | $-13,676,000 | $-13,592,000 | $-12,292,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.60 | $-0.60 | $-0.52 | $-0.65 | $-0.78 |
Company Overview
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
4
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
4 Bullish0 Neutral/Bearish
Price Targets
$7
Average Target
↓ 13.5% Downside
Now
$7
Low
$7
Average
$8
High
Based on 3 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 14th 2025 | Cantor Fitzgerald | Resumed | Overweight | - |
| October 30th 2025 | TD Cowen | Initiation | Buy | - |
| October 7th 2024 | H.C. Wainwright | Initiation | Buy | $7 |
| April 24th 2024 | Craig Hallum | Resumed | Buy | $8 |
| June 22nd 2023 | Oppenheimer | Upgrade | Outperform | $7 |
Earnings History & Surprises
DMACBeat Rate
56%
Last 18 quarters
Avg Surprise
+8.9%
EPS vs Estimate
Beats / Misses
10/3
5 met exactly
Latest EPS
$-0.17
Q4 2025
EPS Surprise History
Q1 24
0.0%
$-0.14vs$-0.14
Q2 24
+12.5%
$-0.14vs$-0.16
Q3 24
+18.8%
$-0.13vs$-0.16
Q4 24
0.0%
$-0.15vs$-0.15
Q1 25
-5.9%
$-0.18vs$-0.17
Q2 25
0.0%
$-0.18vs$-0.18
Q3 25
0.0%
$-0.18vs$-0.18
Q4 25
-13.3%
$-0.17vs$-0.15
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 16, 2026 | $-0.17 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.15 | $-0.17 | -13.3% | ✗ MISS |
Q3 2025 | Aug 12, 2025 | $-0.18 | $-0.18 | 0.0% | = MET |
Q2 2025 | May 13, 2025 | $-0.18 | $-0.18 | 0.0% | = MET |
Q1 2025 | Mar 17, 2025 | $-0.17 | $-0.18 | -5.9% | ✗ MISS |
Q4 2024 | Nov 13, 2024 | $-0.15 | $-0.15 | 0.0% | = MET |
Q3 2024 | Aug 7, 2024 | $-0.16 | $-0.13 | +18.8% | ✓ BEAT |
Q2 2024 | May 8, 2024 | $-0.16 | $-0.14 | +12.5% | ✓ BEAT |
Q1 2024 | Mar 19, 2024 | $-0.14 | $-0.14 | 0.0% | = MET |
Q4 2023 | Nov 13, 2023 | $-0.14 | $-0.12 | +14.3% | ✓ BEAT |
Q3 2023 | Aug 14, 2023 | $-0.22 | $-0.16 | +27.3% | ✓ BEAT |
Q2 2023 | May 15, 2023 | $-0.16 | $-0.20 | -25.0% | ✗ MISS |
Q1 2023 | Mar 28, 2023 | $-0.14 | $-0.14 | 0.0% | = MET |
Q4 2022 | Nov 9, 2022 | $-0.13 | $-0.12 | +7.7% | ✓ BEAT |
Q3 2022 | Aug 10, 2022 | $-0.16 | $-0.13 | +18.8% | ✓ BEAT |
Q2 2022 | May 4, 2022 | $-0.20 | $-0.13 | +35.0% | ✓ BEAT |
Q1 2022 | Mar 14, 2022 | $-0.16 | $-0.10 | +37.5% | ✓ BEAT |
Q4 2021 | Nov 10, 2021 | $-0.23 | $-0.18 | +21.7% | ✓ BEAT |
Q3 2021 | Aug 11, 2021 | $-0.19 | $-0.17 | +10.5% | ✓ BEAT |
Latest News
DiaMedica Therapeutics Completes Productive In-Person Pre-IND Meeting With FDA For Planned Study Evaluating DM199 In Preeclampsia
📈 PositiveBenzinga•Dec 18, 2025, 01:46 PM
Cantor Fitzgerald Initiates Coverage On DiaMedica Therapeutics with Overweight Rating, Announces Price Target of $25
📈 PositiveBenzinga•Nov 14, 2025, 02:29 PM
DiaMedica Therapeutics Q3 EPS $(0.17), Inline
➖ NeutralBenzinga•Nov 12, 2025, 09:31 PM
DiaMedica Posts Narrower Loss in Q2
📈 PositiveThe Motley Fool•Aug 13, 2025, 02:47 AM
DiaMedica gains on positive mid-stage trial data for lead drug in preeclampsia
📈 PositiveSeeking Alpha•Jul 17, 2025, 03:14 PM
Frequently Asked Questions about DMAC
What is DMAC's current stock price?
DiaMedica Therapeutics Inc. (DMAC) is currently trading at $8.48 per share. The stock has moved +2.05% today.
What is the analyst price target for DMAC?
The average analyst price target for DMAC is $8.33, based on 1 analyst.
What sector is DiaMedica Therapeutics Inc. in?
DiaMedica Therapeutics Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is DMAC's market cap?
DiaMedica Therapeutics Inc. has a market capitalization of $0.44 billion, making it a small-cap company.
Does DMAC pay dividends?
No, DiaMedica Therapeutics Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALT
Altimmune, Inc.
$3.90
Mkt Cap: $0.3B
ANNX
Annexon, Inc.
$5.17
Mkt Cap: $0.6B
DBVT
DBV Technologies S.A.
$22.76
Mkt Cap: $0.5B
DRTS
Alpha Tau Medical Ltd.
$5.07
Mkt Cap: $0.4B
DSGN
Design Therapeutics, Inc.
$9.68
Mkt Cap: $0.6B
ENGN
enGene Holdings Inc.
$8.69
Mkt Cap: $0.4B
GALT
Galectin Therapeutics Inc.
$4.38
Mkt Cap: $0.3B
GNLX
Genelux Corporation
$4.20
Mkt Cap: $0.2B
IMAB
I-Mab
$3.95
Mkt Cap: $0.3B
KRRO
Korro Bio, Inc.
$7.88
Mkt Cap: $0.1B
Explore stocks similar to DMAC for comparison